Floatz logo

Dilanubicel

Childhood Acute Lymphoblastic Leukemia in Remission

Nohla Therapeutics, Inc.Cell therapyPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

71 Active assets in the Childhood Acute Lymphoblastic Leukemia in Remission cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Dilanubicel is also rated in:

acute myeloid leukemia, del(5q31-q32)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →